Clinical Trials Browser

Phase 1 × sapanisertib × Clear all

NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1 Active not recruiting

22 enrolled 14 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT02142803 2026-04-29

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02503722 2026-04-13

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

83 enrolled 21 charts

GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

NCT03154294 2024-07-26

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Phase 1 Completed

19 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Phase 1 Terminated

40 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03017833 2023-10-04

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03370302 2023-02-08

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Phase 1 Terminated

28 enrolled 33 charts

Advanced Nonhematological Neoplasms

NCT02197572 2023-01-23

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Phase 1 Completed

44 enrolled 25 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02719691 2022-07-25

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Phase 1 Completed

47 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Phase 1 Completed

35 enrolled

Other solid neoplasm

Recurrent Malignant Solid Neoplasm

NCT01058707 2020-04-01

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Phase 1 Completed

198 enrolled 28 charts

Advanced Solid Malignancies

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT02412722 2020-02-28

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

Phase 1 Completed

61 enrolled 33 charts

Non-hematologic Malignancy

NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Phase 1 Completed

81 enrolled 33 charts

Advanced Nonhematologic Malignancies

NCT01899053 2019-10-30

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Phase 1 Completed

101 enrolled 54 charts

Advanced Nonhematologic Malignancies

NCT01351350 2019-08-08

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Phase 1 Completed

68 enrolled 29 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03205891 2018-01-17

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Phase 1 Withdrawn

Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT01118689 2013-08-02

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Phase 1 Completed

39 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma